Unlike symptomatic carotid stenosis, ACAS carries a low risk for ipsilateral stroke and in the current ''aggressive'' therapeutic approach with statins and hypertension lowering drugs, the risk of strokes is even smaller. Therefore, the number needed to treat by CEA increases.
However, it is obvious that there is a sub-group of ACAS patients with higher risk of stroke than average, in whom surgery might be justified. An attempt to identify this subgroup (or sub-groups) by using advanced imaging techniques like TCD and Doppler were carried out, and a current study where TCD with microemboli detection (MES) was used revealed encouraging positive results (Lancet Neurol. Published online May 28, 2010).
Taking all the above mentioned arguments in consideration it is clear that CEA might have a beneficial effect in a selected high risk sub-group of ACAS patients that should be identified by using various advanced techniques like MES, as well as MRI to identify the thickness of the fibrous cups or various inflammatory biomarkers to assess plaque activity. These novel techniques may identify the vulnerable thrombogenic atherosclerotic plaque, leading to CEA. Otherwise, aggressive medical therapy of risk factors is recommended.
